ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.2500
-0.1100 (-2.52%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.3600
Open4.3400
Bid4.12 x 800
Ask6.00 x 800
Day's Range4.2100 - 4.3700
52 Week Range4.2000 - 14.4500
Volume178,235
Avg. Volume383,290
Market Cap74.914M
Beta (3Y Monthly)5.35
PE Ratio (TTM)N/A
EPS (TTM)-2.82
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.40
Trade prices are not sourced from all markets
  • Benzinga4 days ago

    The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...

  • GlobeNewswire5 days ago

    Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is reporting new 12-month open label clinical data describing the long term impact of ZYN002 on emotional and behavioral symptoms of Fragile X Syndrome (FXS) in a poster presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology. In a poster entitled, “Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS),” Steven Siegel, M.D., Ph.D., Professor and Chair of the Department of Psychiatry and the Behavioral Sciences at the Keck School of Medicine, University of Southern California, is presenting new 12-month data from the open label Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial of ZYN002 in children and adolescents with FXS.

  • Simply Wall St.5 days ago

    When Will Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Become Profitable?

    Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company’s loss has recently broadened since it announced a -US$32.0m loss in the full Read More...

  • GlobeNewswire24 days ago

    Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE26 days ago

    Opioid Alternatives Could Make Investors Major Gains

    HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...

  • GlobeNewswire27 days ago

    Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 30th Annual Piper Jaffray Healthcare conference. The presentation will take place on November 27, 2018 at 9:50 AM EST at the Lotte New York Palace. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • Benzingalast month

    Sell-Side Analysts See Upside Potential In Zynerba

    Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) have dropped by about 12 percent since the company reported third-quarter results Nov. 8. Analysts at HC Wainwright and Canaccord Genuity consider the sell-off ...

  • Associated Presslast month

    Zynerba: 3Q Earnings Snapshot

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 47 cents. Zynerba shares have declined 52 percent since the beginning of the year. The stock has dropped 44 percent in ...

  • GlobeNewswirelast month

    Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

    DEVON, Pa., Nov. 08, 2018 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.

  • ACCESSWIRE2 months ago

    Reading Filings to Predict Future Events

    HENDERSON, NV / ACCESSWIRE / November 1, 2018 / One of the best ways to predict major announcements is by pouring through filings. Sometimes you can find interesting bits that may signal larger announcements. ...

  • Benzinga2 months ago

    Short Sellers Are Making Huge Profits In Cannabis Stocks

    Cannabis stocks went on a spectacular run in the months prior to the Oct. 17 Canadian legalization. The overheated group has run out of steam in recent weeks, however, and short sellers have been on the ...

  • Investopedia2 months ago

    Medical Cannabis Stocks Vs. Recreational Cannabis Stocks: Which Ones Should You Invest In?

    Broadly the industry is divided into two markets: the market for medical marijuana and the one for recreational marijuana. According to a report released by research firm ArcView Market Research and BDS analytics, the overall share of the medical marijuana industry slid from 100% in 2013 to 71% in 2017. As of this writing, nine states have completely legalized recreational marijuana.) By 2027, medical marijuana will be just 33% of the overall market states ArcView.

  • Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • Beverage Giants Buying Into The Cannabis Boom
    Oilprice.com2 months ago

    Beverage Giants Buying Into The Cannabis Boom

    The beverage sector is one of the most profitable in the markets, and now these billion-dollar giants are getting in on the next great North American industry

  • InvestorPlace3 months ago

    2 Marijuana Biotechs to Watch

    On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.

  • ACCESSWIRE3 months ago

    The Hottest CBD Stocks

    HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because ...

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2018 Cantor Global Healthcare conference. The presentation will take place on October 1, 2018 at 2:55 PM EDT at the InterContinental New York Barclay Hotel. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • Benzinga3 months ago

    Cantor Fitzgerald's 7 Buys For 7 Biotechs

    Cantor Fitzgerald has high hopes for patients with rare and orphan diseases.  “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...

  • Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
    Zacks3 months ago

    Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • ACCESSWIRE3 months ago

    CBD Stocks Set to Explode

    HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...

  • What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?
    Simply Wall St.3 months ago

    What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?

    I’ve been keeping an eye on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believeRead More...

  • Zynerba Pharmaceuticals Continues Its 3-Day Rally
    InvestorPlace4 months ago

    Zynerba Pharmaceuticals Continues Its 3-Day Rally

    The stock went from its closing price of $6.80 on Tuesday and finished the day off sitting at $8.00. This represents an 17%-increase for Zynerba Pharmaceuticals on Wednesday. Now the rally for ZYNE stock is still going strong on Thursday, Aug. 30, 2018.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Zynerba Pharmaceuticals Inc Earnings Call